

Returns

As at 30 April 2025	1m %	3m %	1y %	3y % pa	5y % pa	Since inception % pa (Nov 13)
Gross	2.5	-6.9	1.3	0.4	4.1	10.4
Net of Fees	2.5	-6.9	1.3	0.4	4.0	9.6
S&P Biotechnology Select Industry Index (converted to AUD)	0.7	-12.9	0.9	7.9	-1.7	11.1

Portfolio Composition

NAV per share	% in cash	% shares in USD	% shares in AUD
1.60*	18.8	53.2	28

Commentary

April was a month dominated by news of tariffs introduced by the US administration. As stated previously, I do not expect tariffs to have any impact on the long term trends underpinning our investments, namely aging and chronic disease. I took advantage of the volatility to add to our positions in Wuxi Biologics and Telix.

Biotech funding continues to drop to a low of \$8b in quarter 1 of 2025, down from \$18b in quarter 1 of 2024. Drug pipelines continued to be pruned, with the most recent news of giant Astra Zeneca withdrawing from neuro, and Pfizer discontinuing its obesity drug candidate.

Earnings report at the end of April appear to confirm that destocking has now come to an end, and the recovery in bioprocessing continues as big pharma reprioritised and refocussed on commercial launch activities. Three major pharmaceutical companies have announced a cumulative investment of over US\$150b over the next few years to ramp up manufacturing capabilities in the US. This should provide a continuing tailwind to the bioprocessing sector. About 18% of the CE portfolio is exposed to bioprocessing (see Appendix 2).

Thank you for your trust and confidence in us.

Regards

Peter Phan

Portfolio Manager

Appendix 1: Gross Monthly Returns

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	SPSIBI
2022	-5.5	0	0.5	-4.5	1.0	-0.5	2.0	-1.0	-5.0	2.0	4.0	-0.5	-7.5	-20.4
2023	2.0	2.0	-1.2	1.8	-2.3	0.0	5.4	-5.7	-3.0	-7.5	6.1	6.4	2.9	6.9
2024	1.2	1.0	0.5	-7	2.5	-1.8	0.0	3.1	0.0	-3.5	2.5	1.2	-1.2	10.6
2025	4.8	-2.5	-6.6	2.5									-2.5	-10.3

SPSIBI = S&P Biotechnology Select Industry Index (converted to AUD)

Appendix 2: Portfolio Composition

Functional Sub-Sectors*	% of portfolio
Cash	18.8%
Software/Data	22.9%
Tools and Devices	15.8%
Bioprocessing	18.2%
Genomics	3.3%
Radiopharma	10.4%
Drug Discovery	2.6%
Legacy- Financial Industry	8.0%

Industry Sectors*	% of portfolio
Cash	18.8%
Life Sciences	35.8%
Healthcare	37.9%
Legacy- Financial Industry	8.0%

Business Model Categories*	% of portfolio
Cash	18.8%
Picks and Shovels	66.5%
Services	6.7%
Infrastructure	0%
Legacy- Financial Industry	8.0%

Appendix 3: CE NAV

CE commenced on 1 November 2013 with shares issued at \$1 per share, backed by \$1 of cash per share.

CE NAV is after payment of dividend and director fees in calendar month February of each year. These payments “reset” the NAV as follows:

- (a) 1.52 to 1.34 in Feb 2017
- (b) 1.46 to 1.39 in Feb 2018
- (c) 1.39 to 1.39 in Feb 2019
- (d) 2.29 to 2.10 in Feb 2020
- (e) 2.53 to 2.25 in Feb 2021
- (f) 2.03 to 1.77 in Feb 2022
- (g) 1.77 to 1.65 in Feb 2023
- (h) 1.65 to 1.65 in Feb 2024
- (i) 1.72 to 1.72 in Feb 2025